证券代码：301111 证券简称：粤万年青 公告编号：2025-037 广东万年青制药股份有限公司 第三届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日在 公司会议室以现场和通讯表决的方式召开公司第三届董事会第八次会议，此前公 司于 2025 年 8 月 16 日以电子邮件形式向全体董事发出会议通知。会议由公司董 事长欧先涛先生召集并主持，本次会议应出席的董事 7 名，实际出席的董事 7 名 （其中董事欧泽庆先生和独立董事李华青先生、杨学儒先生以通讯方式出席并行 使表决权）。公司监事、高级管理人员列席了本次会议。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2025 年半年度募集资金存放与实际使用情况的专项报告》。 表决结果：7 票同意，0 票反对，0 票弃权 1 （三）审议通过了《关于修订<公司章程>的议案》 本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中 华人民共和国证 ...

Core Insights - The company reported a revenue of 155 million yuan for the first half of 2025, reflecting a year-on-year growth of 1.58% [1] - The net profit attributable to the parent company was -7.2249 million yuan, indicating a shift from profit to loss compared to the previous year [1] - The basic earnings per share were -0.0452 yuan, highlighting the financial challenges faced during the reporting period [1] Financial Performance - Revenue for the first half of 2025: 155 million yuan, up 1.58% year-on-year [1] - Net profit: -7.2249 million yuan, a decline from profit to loss [1] - Basic earnings per share: -0.0452 yuan [1] Business Development - The decline in profit is primarily attributed to the new "two-wing business" which is still in the market cultivation phase [1] - Significant costs incurred due to phase-specific investments have impacted overall profitability [1]

广东万年青制药股份有限公司 2025 年半年度报告全文 广东万年青制药股份有限公司 1 广东万年青制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人欧先涛、主管会计工作负责人陈秀燕及会计机构负责人(会计 主管人员)陈星宇声明：保证本半年度报告中财务报告的真实、准确、完整。 2025-039 2025 年 8 月 27 日 2025 年半年度报告 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，投 资者均应对此保持足够的风险认识，并应当理解计划、预测与承诺之间的差 异，请投资者注意投资风险。 有关公司可能面对的风险及公司应对措施等详见本报告"第三节管理层讨论 与分析，十、公司面临的风险与应对措施"，敬请各位投资者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 第一节 重要提示、目录和释义 | | 2 | ...

广东万年青制药股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 证券代码：301111 证券简称：粤万年青 公告编号：2025-036 广东万年青制药股份有限公司（以下简称"公司"）于近日收到公司控股股东 广东金欧健康科技有限公司（以下简称"金欧健康"）的通知，获悉金欧健康将其 持有的公司部分股份办理了质押手续，现将具体情况公告如下： （一）股东股份质押的基本情况 1、本次股份质押基本情况 | 股东名 | | 是否为控股 股东或第一 | 本次质 押数量( | 占其所 持股份 | 占公司 总股本 | 是否为限售 股(如是，注 | 是否 为补 | 质押 起始 | 质押到 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | | 大股东及其 | 万股) | 比例 | 比例 | 明限售类型 | 充质 | 日 | 期日 | | 用途 | | | | 一致行动人 | | | ...

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is transforming from a traditional Chinese medicine enterprise into a comprehensive health group by integrating medicine, health food, and medical services, leveraging its long history and technological innovation [1][4]. Group 1: Company Overview - Guangdong Wannianqing has over 130 years of history and has been recognized as a "Chinese Time-Honored Brand" by the Ministry of Commerce in 2024, marking its craftsmanship and quality in the traditional Chinese medicine market [1][2]. - The company currently holds 101 drug approvals, 32 original innovative products, and 38 products listed in the national medical insurance catalog, with key products including Shenshuijian Sugar-Lowering Tablets and Yixin Pills [1][2]. Group 2: Innovation and Technology - The company is implementing a "traditional craftsmanship + intelligent manufacturing" development model, focusing on modernizing production while preserving traditional techniques [3][4]. - Innovative technologies such as vacuum low-temperature belt technology and ultra-fine pulverization are being utilized to enhance the efficiency and quality of traditional Chinese medicine production [3][4]. Group 3: Research and Development - Guangdong Wannianqing employs a "dual-wheel drive" model for R&D, focusing on both independent and collaborative research, particularly in areas like gallbladder and cardiovascular drugs [4]. - The company collaborates with Shantou University to promote the rapid transformation of research results into practical applications, enhancing its core competitiveness [4]. Group 4: Market Expansion and Ecosystem - The company is building a comprehensive health ecosystem that integrates pharmaceutical manufacturing, healthcare, and health consumer products, aiming to transition into a comprehensive health group [5][6]. - Recent acquisitions, such as the 85% stake in Guangdong Tongren Pharmaceutical Co., Ltd., allow the company to better control the quality of medicinal materials and streamline the production process [5][6]. - The company is also expanding its health food business, focusing on high-end products like bird's nest and health teas, and plans to establish a "China Bird's Nest Port" in Shantou to enhance supply chain management [6].

Company Overview - Yue Wannianqing's stock price is reported at 17.97 yuan, down 1.70% from the previous trading day [1] - The opening price for the day was 18.40 yuan, with a high of 18.55 yuan and a low of 17.75 yuan, resulting in a trading volume of 58,600 hands and a transaction amount of 106 million yuan [1] Industry Position - Yue Wannianqing operates in the traditional Chinese medicine industry, with business segments including pharmaceuticals, Chinese medicinal pieces, and health supplements [1] - The company holds dual certifications as a "Chinese Time-honored Brand" and "Intangible Cultural Heritage," indicating its strong market position [1] Strategic Initiatives - Recently, the company participated as a key co-organizer and exhibitor at the first Shantou Health Industry Innovation Development Conference and Health Product Expo, showcasing its innovative capabilities and strategic layout in the "Chinese Medicine +" industry chain [1] - Yue Wannianqing established strategic cooperation with the Jinping District government and Shantou University during the expo [1] - The company also hosted the "Whole Life Cycle Health Innovation Development Forum" and conducted a special roadshow event [1] Financial Insights - On August 12, the net outflow of main funds was 2.4228 million yuan, accounting for 0.08% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 4.2846 million yuan, representing 0.15% of the circulating market value [1]

Group 1 - The first Shantou Health Industry Innovation Development Conference and Health Product Expo was successfully held from August 8 to 10, 2025, with the theme "Healthy China, Vibrant Shantou" [1] - Guangdong Wannianqing Pharmaceutical Co., Ltd. (referred to as "Yue Wannianqing") participated deeply as an important co-organizer and exhibitor, showcasing its innovative capabilities and strategic layout covering the "Traditional Chinese Medicine +" industry chain [1] - Yue Wannianqing's business scope includes pharmaceuticals, traditional Chinese medicine pieces, and health supplements, and it presented its core sectors such as Huahuaitang Traditional Chinese Medicine Hall and various health service centers [1] Group 2 - During the opening ceremony, Yue Wannianqing's Chairman Ou Xiantao and Vice President Chen Xiuyan participated in the launch and signing of several important projects, including a strategic cooperation with the Jinping District Government and Shantou University, marking a new stage in government-enterprise collaborative development [1] - Following the expo, Yue Wannianqing, in collaboration with the Shantou Listed Companies Development Promotion Association and Guangzhou Private Equity Fund Association, held a themed roadshow focusing on "Value Management and High-Quality Development," attracting numerous listed companies, excellent enterprises, investment institutions, and financial media [2] - The company, recognized as a "Chinese Time-Honored Brand" and a "Cultural Heritage," is actively responding to the national strategy for revitalizing traditional Chinese medicine and seizing historical opportunities for high-quality development in the health industry [2]

证券代码：301111 证券简称：粤万年青 公告编号：2025-035 广东万年青制药股份有限公司 关于持股5%以上股东减持股份触及1%暨减持计划实施完毕 的公告 公司股东合和投资控股（广州）合伙企业（有限合伙）保证向本公司提供 的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日在巨 潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东股份减持计划的 预披露公告》（公告编号：2025-030），股东合和投资控股（广州）合伙企业（有 限合伙）（以下简称"合和投资"）计划自该公告披露之日起十五个交易日后的 三个月内以集中竞价交易、大宗交易方式合计减持公司股份不超过 4,800,000 股， 即减持比例不超过公司总股本的 3.00%。 公司近日收到合和投资出具的《告知函》,获悉合和投资于 2025 年 8 月 5 日 -2025 年 8 月 7 日期间，通过大宗交易的方式累计减持公司股份 1,052,700 股， 占公司总股本的比 ...

Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. has experienced a decline in its stock price and financial performance, indicating potential challenges for the company [1][3]. - As of August 8, 2025, the stock price of Guangdong Wannianqing is 18.23 yuan, down 3.44%, with a turnover rate of 6.16% and a trading volume of 98,500 hands, amounting to 181 million yuan [1]. - The company reported total revenue of 70.81 million yuan for the first quarter of 2025, a year-on-year decrease of 0.54%, and a net profit attributable to shareholders of 3.44 million yuan, down 129.32% year-on-year [1]. Group 2 - The company has made investments in 10 enterprises and participated in 4,604 bidding projects, indicating active engagement in business development [2]. - Guangdong Wannianqing holds 51 trademark registrations and 47 patents, showcasing its focus on intellectual property [2]. - The company has 133 administrative licenses, reflecting its compliance and operational capabilities within the pharmaceutical industry [2].

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. announced that its major shareholder, Hehe Investment Holdings (Guangzhou) Partnership, plans to reduce its shareholding by up to 4,800,000 shares, representing a maximum of 3.00% of the company's total share capital [1][3]. Summary by Sections Shareholder Reduction Plan - Hehe Investment plans to reduce its holdings within three months starting from fifteen trading days after the announcement date [1][3]. - The reduction will be executed through centralized bidding and block trading methods [1][3]. Recent Shareholding Changes - On August 4, 2025, Hehe Investment reduced its holdings by 895,000 shares, decreasing its ownership from 8.2173125% to 7.6579375%, which is a change of 1% of the total share capital [2]. - The total shares held by Hehe Investment after the reduction are 1,225.27 million shares [2]. Compliance and Regulations - The reduction is in line with the previously disclosed reduction plan, and the actual number of shares reduced does not exceed the planned amount [3][4]. - The company confirms that the reduction does not violate any laws or regulations, and there are no restrictions on the shares being reduced [3][4].